FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy-Reference-Cited by-同舟云学术

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Published:2015-07-17 Issue:19 Volume:21 Page:4257-4261
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kim Geoffrey,Ison Gwynn,McKee Amy E.,Zhang Hui,Tang Shenghui,Gwise Thomas,Sridhara Rajeshwari,Lee Eunice,Tzou Abraham,Philip Reena,Chiu Haw-Jyh,Ricks Tiffany K.,Palmby Todd,Russell Anne Marie,Ladouceur Gaetan,Pfuma Elimika,Li Hongshan,Zhao Liang,Liu Qi,Venugopal Rajesh,Ibrahim Amna,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 440 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report;Gynecologic Oncology;2024-11

2. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications;European Journal of Medicinal Chemistry;2024-09

3. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

4. Evaluation of Anticancer Efficacy of D-α-Tocopheryl Polyethylene-Glycol Succinate and Soluplus® Mixed Micelles Loaded with Olaparib and Rapamycin Against Ovarian Cancer;International Journal of Nanomedicine;2024-08

5. Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients;Gynecologic Oncology;2024-08